Cargando…

2387. Assessment of COVID-19 primary series vaccination and factors associated with early and late uptake among Servicemembers in the Military Health System

BACKGROUND: Identifying predictors of COVID-19 vaccination receipt in servicemembers (SM) is critical for protecting US military health. We report active-duty (AD) SM vaccination across 20 months of eligibility and assess factors associated with adoption of the primary series vaccine pre/post the De...

Descripción completa

Detalles Bibliográficos
Autores principales: Stewart, Laveta, Craig-Kuhn, Megan Clare, Sercy, Erica, Stern, Caryn, Graham, Brock, Michel, Amber, Parmelee, Edward, Shackelford, Stacy, Pollett, Simon, Burgess, Timothy, Tribble, David R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678410/
http://dx.doi.org/10.1093/ofid/ofad500.2007
Descripción
Sumario:BACKGROUND: Identifying predictors of COVID-19 vaccination receipt in servicemembers (SM) is critical for protecting US military health. We report active-duty (AD) SM vaccination across 20 months of eligibility and assess factors associated with adoption of the primary series vaccine pre/post the Department of Defense (DoD) mandate, 8/24/21. [Figure: see text] METHODS: Data on AD, National Guard/Reserve on AD, ages >17, Military Health System (MHS) beneficiaries (1/1/20 - 6/30/22) were extracted from the MHS Data Repository. Descriptive statistics were assessed using Chi-square. Univariate and multivariate modeling was conducted to examine the relationship of demographics and COVID-19 diagnosis with initiation of the COVID-19 primary series vaccine pre mandate. Statistical significance was defined as p< 0.05. RESULTS: Of 1,889,750 SMs, most were ages 17-49, male, lived in the US, white, not Hispanic, and served in the Army. Overall, 90% received >1 primary series dose; with 85% completing the primary series, 5% had partial primary series, and 10% had no record of vaccination at the end of observed time. Of SMs with >1 primary series dose, 78% received the 1st dose pre mandate (11% had COVID-19 prior to 1(st) dose) and 22% post mandate (19% had COVID-19 prior to 1(st) dose; p< 0.001) (Table 1 and Fig. 1). SM ages >50 had higher odds of vaccine initiation pre mandate (P< 0.001), compared to ages 17-49 (Table 2). States in the Midwest and North central US had lower odds of pre mandate initiation compared to states in the southeast, aOR=0.85 and 0.87 respectively. Black/African American SM had lower odds (aOR=0.71) of pre mandate initiation, and Asians or Pacific Islanders had higher odds (aOR=1.78) (P< 0.001) compared to white SM (Table 2). Coast Guard and Navy had higher odds of pre mandate initiation; Air Force and Marine Corps had lower odds (P< 0.001) compared to Army. SM who had COVID infection prior to 1(st) primary dose had lower odds (P< 0.001) of initiating pre mandate. [Figure: see text] 1 Domestic regions of residence are defined by Health and Human Services (HHS) regions and all others are considered outside the US. [Figure: see text] [Figure: see text] 1 The model was adjusted for all factors shown in the table: age, gender, region of residence, race, Hispanic ethnicity, branch of service, COVID-19 infection prior to initiation primary series, and active-duty status. 2 Domestic regions of residence are defined by Health and Human Services (HHS) regions and all others are considered outside the US. CONCLUSION: Although the majority of SM initiated the COVID-19 primary series prior to the DoD mandate, age, race, history of COVID-19 diagnosis, and region were associated with uptake post-mandate. Understanding the factors that affect vaccine uptake among SM is important to guide vaccine policy to enhance medical readiness and optimal vaccine effectiveness. DISCLOSURES: Simon Pollett, MBBS, AstraZeneca: The IDCRP and the Henry M. Jackson Foundation (HJF) were funded to conduct an unrelated phase III COVID-19 monoclonal antibody immunoprophylaxis trial Timothy Burgess, MD, MPH, AstraZeneca: The IDCRP and the Henry M. Jackson Foundation (HJF) were funded to conduct an unrelated phase III COVID-19 monoclonal antibody immunoprophylaxis trial